DelveInsight's "Pediatric Growth Hormone Deficiency (PGHD) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pediatric Growth Hormone Deficiency market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Pediatric Growth Hormone Deficiency market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Pediatric Growth Hormone Deficiency (PGHD): An Overview
Pediatric Growth Hormone Deficiency (PGHD) occurs when the pituitary gland does not make enough growth hormone. It can be caused by damage to the pituitary gland or another gland called the hypothalamus. The injury can occur before birth (congenital) or during or after birth (acquired).
PGHD can be congenital (children are born with the condition), acquired (brain tumor, head injuries, or other causes), iatrogenic (induced by treatment for cancer), or idiopathic (of unknown cause). The consequences of PGHD can range from severe to moderate. The child is more at risk for GH deficiency if they have any of these, like brain injury, brain tumor, or radiation treatment to the head.
Pediatric Growth Hormone Deficiency (PGHD) Market Key Facts
-
The study by Rogol stated that GHD in children is a relatively rare condition. In the United States, it was estimated to occur in approximately 1 in 3500 to 4000 children.
-
As per the study by Walter et al., the prevalence of GHD ranges between 1:3500 and 1:8700 in Germany.
-
According to the Boston Children's Hospital, about one in 4,000 to 10,000 children develop GHD.
-
As per National Institute for Health and Clinical Excellence (NICE), the prevalence of growth hormone deficiency was estimated to be between 1 in 3500 and 1 in 4000 children. In about half of the children with growth hormone deficiency (50%), the cause is unknown (idiopathic growth hormone deficiency).
-
According to the NORD, GHD affects males and females equally. However, given the greater concern for boys with short stature in most societies, diagnosis tends to favor males over females. About 73% of patients with idiopathic GHD in the NCGS were males. Additionally, patients with GHD from organic causes such as tumors and radiation, in which no gender bias should be present, were still 62% males.
-
According to Brod et al., the prevalence of childhood GHD reported in published studies was within the range of 1.8–2.9 per 10,000 in Europe and the US.
Pediatric Growth Hormone Deficiency (PGHD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Pediatric Growth Hormone Deficiency market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Pediatric Growth Hormone Deficiency market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Pediatric Growth Hormone Deficiency (PGHD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Pediatric Growth Hormone Deficiency (PGHD) Epidemiology Segmented by -
-
Total Prevalent Pool of GHD (2019–2032)
-
Total Prevalent Pool of PGHD (2019–2032)
-
Diagnosed and Treatable Pool of PGHD (2019–2032)
Pediatric Growth Hormone Deficiency (PGHD) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Pediatric Growth Hormone Deficiency market or expected to be launched during the study period. The analysis covers the Pediatric Growth Hormone Deficiency market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Pediatric Growth Hormone Deficiency pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Pediatric Growth Hormone Deficiency Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/pediatric-growth-hormone-deficiency-market
Pediatric Growth Hormone Deficiency (PGHD) Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Pediatric Growth Hormone Deficiency. Currently, Ascendis Pharma A/S is leading the therapeutics market with its Pediatric Growth Hormone Deficiency drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Pediatric Growth Hormone Deficiency (PGHD) Therapeutic Market Incldue:
-
Ascendis Pharma
-
OPKO Health
-
Aravive
-
Lumos Pharma
-
I-MAB Biopharma
-
Novo Nordisk
And Many Others
Pediatric Growth Hormone Deficiency (PGHD) Drugs Covered in the Report Include:
-
Lonapegsomatropin: Ascendis Pharma A/S
-
Somatrogon: OPKO Health
-
Somapacitan: Novo Nordisk
-
LUM-201: Lumos Pharma
-
TJ101: I-MAB Biopharma
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/pediatric-growth-hormone-deficiency-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Pediatric Growth Hormone Deficiency Competitive Intelligence Analysis
4. Pediatric Growth Hormone Deficiency Market Overview at a Glance
5. Pediatric Growth Hormone Deficiency Disease Background and Overview
6. Pediatric Growth Hormone Deficiency Patient Journey
7. Pediatric Growth Hormone Deficiency Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Pediatric Growth Hormone Deficiency Treatment Algorithm, Current Treatment, and Medical Practices
9. Pediatric Growth Hormone Deficiency Unmet Needs
10. Key Endpoints of Pediatric Growth Hormone Deficiency Treatment
11. Pediatric Growth Hormone Deficiency Marketed Products
12. Pediatric Growth Hormone Deficiency Emerging Drugs and Latest Therapeutic Advances
13. Pediatric Growth Hormone Deficiency Seven Major Market Analysis
14. Attribute Analysis
15. Pediatric Growth Hormone Deficiency Market Outlook (In US, EU5, and Japan)
16. Pediatric Growth Hormone Deficiency Access and Reimbursement Overview
17. KOL Views on the Pediatric Growth Hormone Deficiency Market
18. Pediatric Growth Hormone Deficiency Market Drivers
19. Pediatric Growth Hormone Deficiency Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/pediatric-growth-hormone-deficiency-market
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
